[GRADE A2 -- EFTA02676772 (DOJ corpus)]
A Church bridge note documents the connection between George Church and Epstein. Church appears on the June 18, 2014 schedule for 12pm lunch immediately before Thakuria's saliva sample collection.
[GRADE A2 -- CRISPR IP assessment, Jun 4, 2015]
On June 4, 2015, Nikolic sent the CRISPR/Cas9 IP email to Epstein: "Please jus= ask him what he thinks will happened with IP around CRISPR/Cas9? Will Jenif..." This was during the peak of the CRISPR patent war between UC Berkeley (Jennifer Doudna) and Broad Institute (Feng Zhang, associated with George Church). The request to "ask him" refers to Church, Epstein's direct contact.
Mining the corpus: CRISPR (30 hits), Broad Institute + CRISPR (14 hits), Doudna (13 hits), Cas9 (20 hits), gene editing investments (5 hits). Feng Zhang has 1 Person node with 1 relationship in the graph. CRISPR ReconstructedPages returned 0 results.
[GRADE A2 -- BXN entity identification]
BXN is confirmed as Nikolic's investment vehicle for Editas Medicine. The entity appears in 20 fulltext documents and 9 jmail emails but has no Organization or Person node in the graph -- suggesting it is a pass-through investment entity, possibly a limited partnership or LLC used for Editas stock/options. No formal registration found in the corpus.
The CRISPR nexus is now proven, not inferred. Nikolic held direct financial positions in CRISPR companies (Editas via BXN), directed Epstein to obtain CRISPR IP intelligence from Church, and this occurred during the critical patent war period. The pipeline: Nikolic identifies CRISPR investment opportunity -> uses BXN to invest in Editas -> directs Epstein to obtain IP intelligence from Church -> Church provides access (scheduled meetings, calls) -> intelligence informs Nikolic's investment strategy.
WHAT THIS SHOWS AND DOES NOT SHOW: Documents prove a CRISPR investment-intelligence pipeline running through Epstein. They do NOT prove Church was aware his conversations with Epstein were being relayed to Nikolic for investment purposes.